PE20230617A1 - Compuestos macrociclicos y metodos de uso de los mismos - Google Patents

Compuestos macrociclicos y metodos de uso de los mismos

Info

Publication number
PE20230617A1
PE20230617A1 PE2022003001A PE2022003001A PE20230617A1 PE 20230617 A1 PE20230617 A1 PE 20230617A1 PE 2022003001 A PE2022003001 A PE 2022003001A PE 2022003001 A PE2022003001 A PE 2022003001A PE 20230617 A1 PE20230617 A1 PE 20230617A1
Authority
PE
Peru
Prior art keywords
amino acid
bond
compounds
sequence
refers
Prior art date
Application number
PE2022003001A
Other languages
English (en)
Inventor
Jakob Fuhrmann
Wayne Fairbrother
Hao Wu
Jeremy Murray
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20230617A1 publication Critical patent/PE20230617A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invencion se refiere a un compuesto que tiene la formula I, donde: X1 es un motivo de union a la ubiquitina ligasa E3 (EULBM), X2 es un D-alfa aminoacido o un D-gamma aminoacido, L2C es un D-alfa aminoacido o un D-beta aminoacido o un enlace, L2A y L2B son un enlace o un aminoacido, L1A, L1B y L1C son cada uno independientemente un enlace o un aminoacido. Los compuestos especificos son seleccionados del grupo que consiste en los compuestos 1, 3, 4, 5, entre otros. Tambien se refiere a un compuesto que comprende un peptido ciclico que comprende una secuencia seleccionada del grupo que consiste en SEQ ID Nos 1-68 y 112-120, donde el extremo aminico del primer aminoacido en dicha secuencia esta unido covalentemente al extremo carboxilico del ultimo aminoacido de dicha secuencia. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son utiles en el tratamiento del cancer o de una condicion fibrotica.
PE2022003001A 2020-06-23 2021-06-22 Compuestos macrociclicos y metodos de uso de los mismos PE20230617A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063043071P 2020-06-23 2020-06-23
PCT/US2021/038503 WO2021262731A2 (en) 2020-06-23 2021-06-22 Macrocyclic compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20230617A1 true PE20230617A1 (es) 2023-04-14

Family

ID=77207221

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022003001A PE20230617A1 (es) 2020-06-23 2021-06-22 Compuestos macrociclicos y metodos de uso de los mismos

Country Status (17)

Country Link
US (1) US20220106361A1 (es)
EP (1) EP4168121A2 (es)
JP (1) JP2023532233A (es)
KR (1) KR20230026461A (es)
CN (1) CN115702026A (es)
AR (1) AR122707A1 (es)
AU (1) AU2021297799A1 (es)
BR (1) BR112022026364A2 (es)
CA (1) CA3185149A1 (es)
CL (2) CL2022003643A1 (es)
CO (1) CO2022018532A2 (es)
CR (1) CR20220658A (es)
IL (1) IL299163A (es)
MX (1) MX2022016454A (es)
PE (1) PE20230617A1 (es)
TW (1) TW202219056A (es)
WO (1) WO2021262731A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024020159A1 (en) * 2022-07-21 2024-01-25 Merck Sharp & Dohme Llc Macrocyclic peptides targeting kras

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144233A (en) 1977-02-16 1979-03-13 The Dow Chemical Company Method for preparing benzo-(1,3,4)-benzotriazepines
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
AU765660B2 (en) * 1998-08-20 2003-09-25 Eli Lilly And Company Ring modified cyclic peptide analogs
JP5159305B2 (ja) 2005-05-30 2013-03-06 田辺三菱製薬株式会社 チエノトリアゾロジアゼピン化合物及びその医薬としての用途
JP5478262B2 (ja) 2007-12-28 2014-04-23 田辺三菱製薬株式会社 抗癌剤
EP2496582B1 (en) 2009-11-05 2016-01-27 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
ES2652304T3 (es) 2009-11-05 2018-02-01 Glaxosmithkline Llc Compuesto de benzodiacepina novedoso
WO2011143651A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
BR112012029005A2 (pt) 2010-05-14 2016-07-26 Dana Farber Cancer Inst Inc composições e métodos de tratamento de neoplasia, doença inflamatória e outros distúrbios
ES2526671T3 (es) 2010-06-22 2015-01-14 Glaxosmithkline Llc Compuestos de benzotriazoldiazepina inhibidores de bromodominios
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
KR102088157B1 (ko) 2015-09-02 2020-03-12 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 브로모도메인 억제제로서 사용하기 위한 피리디논 디카복스아미드
JP2021506814A (ja) * 2017-12-15 2021-02-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 安定化ペプチドによって介在される標的タンパク質の分解

Also Published As

Publication number Publication date
CL2022003643A1 (es) 2023-05-26
US20220106361A1 (en) 2022-04-07
IL299163A (en) 2023-02-01
CL2023002555A1 (es) 2024-01-26
CO2022018532A2 (es) 2022-12-30
KR20230026461A (ko) 2023-02-24
CN115702026A (zh) 2023-02-14
CA3185149A1 (en) 2021-12-30
EP4168121A2 (en) 2023-04-26
WO2021262731A3 (en) 2022-02-24
WO2021262731A2 (en) 2021-12-30
AU2021297799A1 (en) 2022-12-22
CR20220658A (es) 2023-04-26
BR112022026364A2 (pt) 2023-01-17
MX2022016454A (es) 2023-03-06
JP2023532233A (ja) 2023-07-27
TW202219056A (zh) 2022-05-16
AR122707A1 (es) 2022-09-28

Similar Documents

Publication Publication Date Title
Parmar et al. Efficient total syntheses and biological activities of two teixobactin analogues
CL2019002167A1 (es) Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)
CY1113379T1 (el) Πεπτιδια κdr και εμβολια που τα περιλαμβανουν
AU2004204031B2 (en) Dimerized peptide
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
RU2014150224A (ru) Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов
PE20151593A1 (es) Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
UY27225A1 (es) Inhibidores de la rho-quinasa
MX2009010965A (es) Péptidos de tem8 y vacunas que los contienen.
CY1113115T1 (el) Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες
PE20230617A1 (es) Compuestos macrociclicos y metodos de uso de los mismos
JP2002502376A (ja) 生物学的膜を横切る輸送を増強するための組成物および方法
CY1108292T1 (el) Αντικαρκινικο σκευασμα που περιεχει dmxaa
EP2651964A2 (en) Croos-linked peptides and proteins, methods of making same, and uses thereof
EA200700976A1 (ru) Соединения в виде молекул-конъюгатов, обладающих повышенной активностью в отношении включения клеткой
ES2450645T3 (es) Análogos quiméricos de somatostatina-dopamina
BRPI0515983A (pt) antagonistas não peptìdicos da bradicinina, composições farmacêuticas compreendendo os mesmos e uso
PE20231074A1 (es) Nuevas proteinas de union a repeticiones de anquirina y sus usos
PE20110344A1 (es) Derivados de etanodiamida como inhibidores de la integrasa del vih
RU2015108999A (ru) Композиции для ногтей
PE20061441A1 (es) Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
US20220340629A1 (en) Myosin Derived Peptides and Related Compounds with Anticoagulant Activities
PE20071313A1 (es) Derivados de cromano como agentes inhibidores de la bomba de acido
RU2592282C1 (ru) Способ получения нонапептидов
ATE405827T1 (de) Screening-verfahren